NCT05060263View on ClinicalTrials.gov

A Study of of HOT1030 in Patients With Advanced Solid Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

March 12, 2021

Primary Completion Date

June 30, 2023

Study Completion Date

June 30, 2023

Conditions
Solid Tumor, Adult
Interventions
DRUG

HOT-1030

HOT-1030 is a Recombinant Humanized CD137 Monoclonal Antibody Injection

Trial Locations (1)

Unknown

RECRUITING

Shanghai Huaota Biopharmaceutical Co., Ltd., Shanghai

Sponsors
All Listed Sponsors
lead

Huabo Biopharm Co., Ltd.

INDUSTRY